Study of rilvegostomig for advanced solid tumors
Part of Cancer clinical trials.
This study tests a new investigational drug, rilvegostomig, given as an injection under the skin. It is for people with advanced solid tumors that have not responded to or have progressed after standard treatments. The goal is to see how the drug behaves in the body and to assess its safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor that is advanced (spread or cannot be removed by surgery).
- You have already received at least one prior cancer treatment, like chemotherapy, immunotherapy, or targeted therapy.
- Your cancer care team agrees that you can pause other cancer treatments for a while to participate.
- You are able to perform daily activities without significant help (ECOG score 0 or 1).
- Your life expectancy is at least 12 weeks.
- Your organs and bone marrow are functioning adequately.
- You weigh at least 30 kg (about 66 pounds).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug that may help people with advanced solid tumors, including liver, stomach, and brain cancers. It is for patients whose cancer has not responded to standard treatments or who cannot have them. The study aims to find the right dose and check safety and effectiveness.
This trial tests a new drug that targets a protein called MET found on some cancer cells. It may help people with certain advanced cancers that have not responded to other treatments.
This trial tests whether a new immunotherapy (rilvegostomig) combined with chemotherapy can help people with advanced stomach or gastroesophageal junction cancer. The study aims to understand how the treatment affects the immune system in the tumor and throughout the body.
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see which drug works better as a first treatment before any other cancer therapy.
This trial tests a new immunotherapy drug, rilvegostomig, against the standard pembrolizumab, both given with chemotherapy, as a first treatment for advanced non-squamous non-small cell lung cancer (NSCLC) that cannot be cured with surgery or radiation. It is for people whose tumors have high PD-L1 levels and do not have certain genetic mutations.
This study tests a new drug (rilvegostomig) alone or with chemotherapy or another drug (ramucirumab) for advanced non-small cell lung cancer that has spread. It aims to see if these combinations work better than standard treatments.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.